Figure 1



Western Blotting Anti-TGFB1
SDS-PAGE
Reducing conditions
(10%)
MW
Mut_Fc
WT_Fc
hR3
99 KD
66 KD
45 KD
31 KD
21 KD
SDS-PAGE
Non-reducing conditions
(7,5%)
MW
Mut_Fc
WT_Fc
hR3
99 KD
66 KD
45 KD

Figure 2




Figure 3



Inhibition of CTLL2 proliferation
5000 cells/wells + IL2 (50 U/mL)
Inhibition of proliferation (%)
100
80
60
40
20
0
0
0,001
0,01
0,1
1
10
Concentration (nM)
TGFB1 commercial
SN Mut/Fc

Figure 4



Neutralization of the Inhibition of CTLL2 proliferation induced by rTGFβ1
5000 cells/wells + IL2 (50 U/mL) + rTGFβ1 (2pM)
% Proliferation
100
50
0
0
0,1
1
10
Concentration (nM)
SN Mut/Fc
anti-TGFB1
hR3

Figure 5




0 Hours
24 Hours
48 Hours
72 Hours
TGF_MT
TGF_WT
No TTO
A
wound width/wound width of day 0
1.0
0.5
0.0
0
1
2
3
Time (days)
MT(0,5ug/ml)
WT(0,5ug/ml)
No TTO

Figura 6


αCD3 (3ug/ml)+IL2 (5ng/ml)+TGFβ1 (0,2nM)
C+
mutTGFβ1.Fc (5,5nM)
mutTGFβ1.Fc (2,75nM)
55.6%
0.12%
3.98%
CD25
Foxp3